On April 10, 2014, the Cochrane Collaboration published an updated review
of randomized clinical trial data for the influenza neuraminidase inhibitor antiviral medications. The review is accompanied by a series of editorials and analyses posted on the British Medical Journal website
. In the review, they raise questions about the value of influenza antiviral medications for the prevention and treatment of influenza.
Based on all available data, including both randomized control trials and observational studies, CDC continues to recommend the use of the neuraminidase inhibitor antiviral drugs (oral oseltamivir and inhaled zanamivir) as an important adjunct to influenza vaccination in the treatment of influenza.
CDC has published a “Have You Heard” article highlighting current influenza antiviral recommendations at http://www.cdc.gov/media/haveyouheard/stories/Influenza_antiviral2.html
For a summary of CDC antiviral guidance for the 2013-2014 influenza season, see:http://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm
Please visit the CDC website at http://www.cdc.gov/flu/antivirals/index.htm
for more information on flu antiviral drugs.